Company Update: Celgene Corporation (NASDAQ:CELG) – Phase II Data for Celgene’s Investigational Oral GED-0301 for Patients with Active Crohn’s Disease Published in New England Journal of Medicine

[Business Wire] – Celgene Corporation today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 in patient Read more on this. Celgene Corporation (CELG), currently . . . → Read More: Company Update: Celgene Corporation (NASDAQ:CELG) – Phase II Data for Celgene’s Investigational Oral GED-0301 for Patients with Active Crohn’s Disease Published in New England Journal of Medicine Similar Articles: Stock Update (NASDAQ:CELG): Celgene Corporation to Webcast at Upcoming Investor Conferences Stock Update: Celgene Corporation (NASDAQ:CELG) – Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress Company Update: Celgene Corporation (NASDAQ:CELG) – Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014